원바이오메드는 진단및 바이오메디컬 연구를 가속화함으로써 인류의 건강 증진을 위한 혁신을 추구하는 분자 생명 과학 회사입니다.
One BioMed는 혁신의 최전선에서 빠르게 성장하고 있는 스타트업입니다. 첫 제품 라인 상용화와 함께 One BioMed에 합류할 수 있는 좋을 기회입니다. 우리와 꿈을 함께할 새로운 도전을 즐기는 인재를 뽑습니다. 이력서와 자기소개서를careers@onebiomed.com으로 보내주시기 바랍니다.
설립자 및 CEO
Dr. Mi Kyoung Park, is the Founder & CEO of One BioMed. As the CEO, she has defined the initial concept of the product, built out the core technologies and mapped out the strategy and execution of the R&D functions. She has 25 years of research experience, covering surface chemistry, nanotechnology, biotechnology and biosensor development, which has resulted in over 60 peer-reviewed publications. Prior to founding One BioMed, she was the head of the Bioelectronics Program at the Institute of Microelectronics, A*STAR, in Singapore, where she managed a multidisciplinary team of 25 scientists and engineers. She was a recipient of an Alexander von Humboldt Research Fellowship, carried out at the Max Planck Institute for Polymer Research in Germany.
Mi Kyoung has a B.E and M.E in Chemical Engineering from Hongik University in South Korea. She went on to receive her Ph.D. in Chemistry from the University of Houston. Mi Kyoung also did a Postdoctoral fellowship at the University of Chicago.
임원 및 이사진
Dr. Nick Roelofs, is an Industrial Advisor at Nordic Capital, a Swedish Private Equity firm and has been a Director and Board Member of One BioMed since 2019. He has a storied career with leadership roles in life science companies such as Baxter Healthcare, Bio-Rad and Applied Biosystems. As the COO, Nick took Strategene public and led the charge at Agilent as President of its Life Science division. Nick has served on the boards of numerous companies, ranging from venture capital backed start-ups, private equity backed companies and MNCs.
Nick received his M.S. degree in Organic Chemistry from Iowa State University and Ph.D. in Chemistry from University of Nevada.
임원 및 이사진
Dr. Heesuk Min, is currently CEO of Medical Partners Korea (MPK) and General Director of its affiliate in Kazakhstan, the first clinic to offer COVID-19 molecular diagnostics in Central Asia. Heesuk has been a Director and Board Member of One BioMed since 2018. Prior to joining MPK, he served as a physician at the Korean Presidential Office in Seoul. He also worked as a Medical Consultant at Samsung Medison and LG Electronics. He is Vice President at Medipreview, an educational institution for medical students in Korea. Over the last 15 years, Heesuk has specialized in complex cardiovascular diseases. He currently consults on the cardiovascular impact of COVID-19.
Heesuk received an M.D. from Seoul National University Medical School and an M.S. in Cardiology from Chung-ang University in South Korea.
임원 및 이사진
Min Suk is the Managing Director of Mirae-N Singapore and Nvestor, a venture capital and private equity firm based in Seoul, South Korea. Hejoined as a Director and Board Member of One BioMed in 2020. Having studied and worked in New York, Hong Kong and Seoul, Min brings extensive international experience in corporate finance, event-driven investment strategy and securities management. He has a track record of taking technologies from concept to commercial reality. His prior work experience spans across equity, trading and consulting companies, such as Bluefin Trading, BGC Partners, Maybank Kim Eng Group, Axial Capital Management and Deloitte. Min also served as a First Lieutenant for 3 years in the Republic of Korea Air Force.
Min received a B.S. in Accounting from the State University of New York at Albany in the United States.
임원 및 이사진
David Ludvigson, is the CEO at Nanomix, a point-of-care diagnostic medical device company, headquartered in Emeryville, California. He joined as a Director and Board Member of One BioMed in March 2021. He is a financial and operating executive with over 35 years of international experience in life sciences and technology companies, including IDEC Pharmaceuticals, Matrix Pharmaceutical, Nanogen, and MIPS Computer Systems. David has overseen the development and launch of numerous new products in the diagnostics arena and has successfully concluded many strategic transactions including multiple acquisitions, corporate partnerships. His financing experience includes venture capital, corporate, lease, bank credit line, IPO and secondary public sources.
David has a B.S. and M.A.S in Accounting from the Gies College of Business, University of Illinois at Urbana-Champaign in the U.S.
상임고문
Dr. Thomas Richards, was the CEO of One BioMed from 2016 to 2017. Since then, he has served as an Executive Advisor to the company. He brings more than 20 years of professional experience in the industries of healthcare and finance. He currently consults to investors and management in the life sciences industry and is a senior advisor to two U.S. based companies, Nanomix and Metis Genetics. Prior to that, Tom led an emerging molecular diagnostics company as the CEO of TessArae, which designed genetic tests for the reproductive health and infectious disease markets. He has also held board positions at several public and private companies in both the healthcare and finance industries. Tom became a life sciences executive after practicing as an academic physician on the clinical faculty of Stanford University and University of California San Francisco, where he was an Assistant Professor of Emergency Medicine. Before attending medical school, Tom began his career as an investment banker in the mergers and acquisitions groups of several firms in New York, including Lazard Frères, UBS and SG Cowen.
Tom received his B.A. in English from Yale University and his M.D. from Harvard Medical School.
의료고문
Dr. Timothy Barkham, is as a Senior Consultant in the Department of Laboratory Medicine at Tan Tock Seng Hospital, and as an Adjunct Associate Professor in the Department of Microbiology and Immunology at the National University of Singapore. Tim is an infectious disease expert and has served on One BioMed’s advisory board since 2016. He worked at the Hammersmith Hospital in London, before moving to Singapore in 1999. He enjoys a mix of clinical and laboratory medicine, teaching, and research. Within Tan Tock Seng, he runs the Travellers’ Health and Vaccination clinic, having developed several commercial diagnostic assays to meet emerging needs, including for SARS-CoV-2.
Tim studied medicine at St. Thomas’ Hospital, London. He received his M.B.B.S and M.Sc. degrees from the University of London. He is also certified as a specialist in Medical Microbiology and Virology and is a fellow of the Royal College of Pathologists.
고문
Dr. Alexander Lezhava, is the Senior Group Leader and a core faculty member at the Genome Institute of Singapore (GIS). He is also the Associate Director at the Office of Strategic and Industry Alliances at GIS. He has served on One BioMed’s advisory board since 2018. The mission of his group at GIS is to work with commercial partners to develop and market molecular diagnostic tools for personalized patient care. Prior to joining GIS, he worked as Research Director at Dx Assays and was a Unit Leader at Riken Research Institute in Japan. His research focus has been to develop genomic technologies and molecular diagnostics for clinical application.
Sandro received his Ph.D. in Microbiology from Hiroshima University in Japan and Master’s degree in Genetics from Ivane Javakhishvili Tbilisi State University, in Georgia.
고문
Mikhail Fedorov, is the Vice President of Strategy and Business Development for Global Strategic Segments at SAP, Singapore. He has served on One BioMed’s advisory board since 2018, bringing more than 23 years of experience in sales and sales leadership, managing customer success and defining Go-to-Market strategies. His prior work experience spans across flagship technology and consulting companies, such as Microsoft, IBM and Deloitte Consulting. Mikhail has also worked in Asia Pacific, Western/Eastern Europe, Russia and the USA with clients from both the Government and Private sectors.
Mikhail has a M.B.A in Management Information Systems from Case Western Reserve University, and a Master of Science in Mechanical Engineering from Budapest University of Technology and Economics. He received his Bachelor’s degree in Mechanical Engineering from Bauman Moscow State Technical University.
고문
Prof. Dong Myung Shin, is currently a faculty at the Department of Chemical Engineering at Hong-ik University in South Korea. He has served on One BioMed’s advisory board since 2018. Prior to joining Hong-ik University Dong Myung was a visiting scholar at the Chemical Engineering Department at Stanford University, Interuniversity Microelectronics Centre, in Belgium, and Electronics and Telecommunications Research Institute, in South Korea. His research interests include LCD photo-alignment, bio-chip interfaces and device manufacturing. He is a member of the Korean Chemical Society, the Polymer Society of Korea, and the Korean Information Display Society, where he served as a Vice-President. He was involved in many projects related to the photochemical and photophysical behavior of organic molecules in microenvironments and tailoring DNA chip interfaces. Dong Myung also served as a research advisor for the LG Display and Amorepacific.
Dong Myung received his Ph.D. in Organic Photochemistry from the University of Rochester in the U.S.
고문
Dr. Joseph Jeong, is a Venture Partner at ARCH Venture Partners. He joined One BioMed’s advisory board in November 2020. Prior to joining ARCH, Joseph was a Co-Founder & Partner at Biopath Ventures, a venture capital firm focused on life sciences tools and diagnostics based in Singapore. Prior to Biopath Ventures, Joseph worked at Applied Ventures, where he invested in industries ranging from biotechnology, semiconductors, displays, and advanced materials. There he raised an innovation fund focused on investing in Korean semiconductor startups. Joseph began his venture capital career at ARCH Venture Partners, leveraging technical and business acumens honed at the Boston Consulting Group and Samsung SDI. In particular, he has carved out a value proposition at the cross-section of semiconductors and life science, championing and leading early investments, most notably in Twist Bioscience and Ultivue.
Joseph received his B.S., M.S. and Ph.D. in Aerospace Engineering from Georgia Institute of Technology and his MBA from University of Chicago Booth School of Business.
고문
Audrey Long, is a Consultant at Biopath Ventures, a venture capital firm focused on life science tools and diagnostics. She joined One BioMed’s advisory board in November 2020. Audrey brings more than 25 years of professional experience in life science marketing and business development in UK, Europe, Japan and USA. Audrey has held positions at Pharmacia (now GE Healthcare), The Automation Partnership, Affymetrix, Illumina and Wako Diagnostics, specializing in micro-fluidics. Prior to joining Biopath Ventures, Audrey also provided consulting services for life science and diagnostics start-ups helping them define strategy, perform market analysis and develop business plans, in addition to fund raising activities.
Audrey received her B.Sc. In Biochemistry from University College Cardiff in Wales, Marketing Dip.M from the Chartered institute of Marketing in London and her M.B.A in Strategy and Marketing from Open University, Cambridge in UK.
고문
Dr. Biju Thomas, is currently a Senior Consultant in Pediatric Respiratory Medicine at KK Women’s and Children’s Hospital, Singapore. He also holds academic appointments with the Duke-NUS Graduate Medical School, Yong Loo Lin School of Medicine and Lee Kong Chian School of Medicine, in Singapore. He has served on One BioMed’s advisory board since 2018. Previously, Biju also worked as a Consultant in Pediatric Respiratory Medicine at the Royal Manchester Children’s Hospital in UK. His clinical special interests include asthma, bronchiectasis, pediatric sleep medicine, Cystic Fibrosis and Primary Ciliary Dyskinesia.
Biju was trained in India, Australia and UK. He did his research M.D. at the University of Leicester, is board certified (CCT) in both Pediatrics and Pediatrics Respiratory Medicine and holds a European Diploma in Pediatric Respiratory Medicine. He is a member of the European Respiratory Society and a fellow of the Royal College of Pediatrics and Child Health.
